🟢 Moderna is trading 4.12% up in pre-market with no fresh company-specific catalyst identified

Moderna is trading 4.12% up now at $155.00 in pre-market, with no fresh company-specific announcement clearly explaining the move.

• It is based on the provided pre-market price, versus $148.87 at the close on September 3, 2026.
• Recent coverage instead highlighted Rothschild & Co. Redburn’s September 3 Sell downgrade, citing valuation concerns after Moderna’s cancer-vaccine rally.
• The earlier melanoma Phase 3 success remains supportive background but appears stale rather than a confirmed overnight catalyst.